Funds with similar focus
|Allos Therapeutics||United States, Westminster|
|Kyoto Chuo Shinkin Bank||Japan, Kyoto|
|Xiamen Dingsheng Zhicheng||China, Xiamen|
|Sarwa Capital||Egypt, Cairo|
|2U Consulting||Germany, Nuremberg|
|Drive by DraftKings||United States, Boston|
|Dongrong Ziben||China, Ningbo|
|Platform Partners||United States, Houston|
|Prologis Ventures||United States, San Francisco|
|BroadOak Capital Partners||United States, Bethesda|
|Indiegogo||United States, San Francisco|
|Obvious Ventures||United States, San Francisco|
|SteelBridge Laboratories||United States, Pittsburgh|
|Melo7 Tech Partners||United States, New York|
|$21M||05 May 2021||United States, Oakland|
|$15M||09 Mar 2021||United States, Mountain View|
|$8M||23 Nov 2020||United States, San Francisco|
|$1M||06 Nov 2020||United Kingdom, London|
|$3M||07 Oct 2020||United States, San Francisco|
|$4M||04 May 2020||United States, Mountain View|
|$18M||11 Mar 2020||United States, Santa Monica|
|$4M||10 Mar 2020||Canada, Victoria|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.